Dr. Choyke on Differences Between PET Scans in Prostate Cancer

Video

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute (NCI), discusses the differences between PET scans in prostate cancer.

When conducing imaging on a patient with prostate cancer, there are 2 typical choices of PET scans—prostate-specific membrane antigen (PMSA) and sodium fluoride PET scans. Choyke says that through a comparative investigation done at NCI, they found that these 2 PET scans do not match up with each other. Early on in the disease course, the imaging from each of these PET scans matches up, but as the disease progresses, they match less, he explains.

Choyke says that this is important because some treatments such as radium-223 dichloride (Xofigo) are very dependent on the bone turnovers, which is reflected in the sodium fluoride PET scan. PSMA-PET, which indicates where the active disease is, does not overlap with the sodium fluoride PET scan, says Choyke. This means that there is a chance that giving radium-223 will do nothing to the cancer. Choyke says that there is work being done to better select patients for radium-223 so that the right patients get the right treatment.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,